SR Pharma Announces key Scientific Publications on Therapeutic RNAi
News Apr 25, 2006
Both articles cover the development and systemic application of Atugen’s siRNA-lipoplex (AtuPLEX) technology for enabling RNA interference in vivo.
In the first article, Atugen’s scientists uncovered the requirement of siRNA formulation to allow functional cellular uptake and delivery in vivo after intravenous administration.
For this purpose Atugen’s proprietary stabilized siRNAs (AtuRNAi) formulated with Atugen’s cationic lipid (AtuFECT) and other components of the AtuPLEX were employed in proof of concept studies to demonstrate and establish target specific and RNAi-mediated knockdown for loss of function analysis in vivo.
Atugen verified the application of the AtuPLEX for inhibiting tumour growth and metastases using appropriate in vivo tumour models as shown in the second publication.
Iain Ross, Executive Chairman of SR Pharma, stated, "Functional delivery has finally been recognised as the key issue for future therapeutic applications of RNAi."
"We are very enthusiastic that Atugen’s scientists have successfully addressed and unravelled this scientific problem. The developed AtuPLEX has all required features to become a novel therapeutic modality for a wide range of human diseases."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.